Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

نویسندگان

  • Brian A. Ference
  • Henry N. Ginsberg
  • Ian Graham
  • Kausik K. Ray
  • Chris J. Packard
  • Eric Bruckert
  • Robert A. Hegele
  • Ronald M. Krauss
  • Frederick J. Raal
  • Heribert Schunkert
  • Gerald F. Watts
  • Jan Borén
  • Sergio Fazio
  • Jay D. Horton
  • Luis Masana
  • Stephen J. Nicholls
  • Børge G. Nordestgaard
  • Bart van de Sluis
  • Marja-Riitta Taskinen
  • Lale Tokgözoğlu
  • Ulf Landmesser
  • Ulrich Laufs
  • Olov Wiklund
  • Jane K. Stock
  • M. John Chapman
  • Alberico L. Catapano
چکیده

Aims To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD). Methods and results We assessed whether the association between LDL and ASCVD fulfils the criteria for causality by evaluating the totality of evidence from genetic studies, prospective epidemiologic cohort studies, Mendelian randomization studies, and randomized trials of LDL-lowering therapies. In clinical studies, plasma LDL burden is usually estimated by determination of plasma LDL cholesterol level (LDL-C). Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD. Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent dose-dependent log-linear association between the absolute magnitude of exposure of the vasculature to LDL-C and the risk of ASCVD; and this effect appears to increase with increasing duration of exposure to LDL-C. Both the naturally randomized genetic studies and the randomized intervention trials consistently demonstrate that any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C, provided that the achieved reduction in LDL-C is concordant with the reduction in LDL particle number and that there are no competing deleterious off-target effects. Conclusion Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This European Atherosclerosis Society (EAS) Consensus Panel overviews current understanding of the pathophysiology of statin-associated myopathy, and provides guidance for diagnosis and management of SAMS. Statin-associated m...

متن کامل

Evidence that Low Density Lipoprotein Is the Primary Cause of Atherosclerotic Cardiovascular Disease: A Bradford-Hill Approach

Cardiovascular disease is the leading cause of death in the Westernized world. The costs in productive lives lost to individuals, families, and society are staggering. The epidemiology, pathogenesis, and preventative treatment are all clearly described. Why then, has this epidemic not been eradicated? One reason is the uncertainty about the primary cause of atherosclerotic cardiovascular diseas...

متن کامل

Atherosclerosis imaging and the future of lipid management.

Lowering low-density lipoproteins (LDL) by statin therapy to reduce the risk for major clinical events in patients with established atherosclerotic cardiovascular disease (ASCVD) represents a therapeutic triumph of modern medicine. With standard doses of statins, the risk for CVD events falls by approximately one third.1 Additional risk reduction occurs by adding other therapeutic modalities to...

متن کامل

A Brief Review of the Association between Genetic Polymorphisms of the Paraoxonase Family and Atherosclerosis

Atherosclerosis is known as an inflammatory disease that can affect any vessel in the body. The occurrence of atherosclerosis in heart vessels is called coronary artery disease (CAD). CAD is one of the most significant causes of morbidity and mortality in developed countries. Different genetic and environmental factors can cause cardiovascular diseases, such as age, weight, sex, and low high-de...

متن کامل

South African dyslipidaemia guideline consensus statement.

The European Society of Cardiology together with the European Atherosclerosis Society published updated dyslipidaemia guidelines in 2011. SA Heart and the Lipid and Atherosclerosis Society of Southern Africa officially adopt these guidelines. This statement adapts aspects of the guidelines to the South African situation. Using the updated Framingham risk charts, interventional strategies are ba...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 38  شماره 

صفحات  -

تاریخ انتشار 2017